Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | MAPK13 | O15264 | 15/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 15/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 15/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 15/20 | 0.61 |
| ▸ | RAF1 | P04049 | 10/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.60 |
| ▸ | BRAF | P15056 | 4/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.56 |
| ▸ | GCGR | P47871 | 4/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6470560 | 0.87 | MAPT (0.65) | MAPTMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2650092 | 0.85 | MAPK13 (0.70) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL2648794 | 0.82 | MAPK14 (0.66) | MAPTMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6465030 | 0.81 | MAPK13 (0.71) | MAPTMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL9193657 | 0.79 | MAPK13 (0.72) | MAPTMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2647400 | 0.79 | MAPK13 (0.73) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL2648771 | 0.79 | MAPK13 (0.72) | MAPTMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6469288 | 0.78 | MAPT (0.65) | MAPT | |
| SCHEMBL2650228 | 0.78 | MAPK13 (0.73) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL2647873 | 0.78 | MAPK13 (0.72) | MAPK13MAPK12MAPK11MAPK14RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | AXXIMA PHARMACEUTICAL AG. (DE) | 2005-09-15 | — | — | US | claimed |
| EP-1532118-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2005-05-25 | — | — | EP | claimed |
| WO-2004005264-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-01-15 | — | — | WO | claimed |
| US-20240000821-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | UNIV JOHNS HOPKINS (US) | 2024-01-04 | — | — | US | disclosed |
| US-20200078387-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | THE JOHNS HOPKINS UNIVERSITY | 2020-03-12 | — | — | US | disclosed |
| WO-2018112342-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | AXXIMA PHARMACEUTICAL AG. (DE) | 2005-09-15 | — | — | US | disclosed |
| EP-1532118-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004005264-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | CSNK1G1, CSNK1E, CSNK1D | MAPT 1480/4885MAPK13 456/4885MAPK12 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.